May 30 |
Precision BioSciences to Participate in Upcoming June Investor Conferences
|
May 29 |
Does Precision BioSciences (DTIL) Have the Potential to Rally 200.55% as Wall Street Analysts Expect?
|
May 17 |
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
|
May 16 |
Deep Dive Into Precision BioSciences Stock: Analyst Perspectives (4 Ratings)
|
May 13 |
Precision BioSciences GAAP EPS of $1.70, revenue of $17.58M beats by $11.56M
|
May 13 |
Precision BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update
|
May 10 |
Precision BioSciences Q1 Earnings Preview
|
May 8 |
Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement
|
May 7 |
Precision BioSciences to Report First Quarter Results on May 13, 2024
|
May 7 |
Precision BioSciences Announces Receipt of FDA Fast Track Designation for ECUR-506, iECURE’s Program for the Treatment of Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency
|